Trial Profile

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jul 2026 According to an Annovis Bio media release, with the last patient expected to complete the 6-month treatment period in January 2027, company expects 6-month symptomatic top-line data readout in Q1 2027 and 18-month disease-modifying top-line data readout in Q1 2028.
18 May 2026 Status changed from recruiting to active, no longer recruiting.
15 May 2026 According to Annovis Bio media release, 85% of patients enrolled; full enrollment on track in summer 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com